ANAB.US AnaptysBio Inc

Healthcare Biotechnology USA Stocks
46.25 USD
Close of Nov 14, 2026
22.01 72.36
Market cap
USD 1.38B
P/E
7.1x
P/B
134.92x
ROE
863.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ANAB.US undervalued?

Graham number

The Graham number of AnaptysBio Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AnaptysBio Inc fundamental analysis

No fundamental analysis for AnaptysBio Inc yet.

AnaptysBio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AnaptysBio Inc

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…

Full company profile